An interventional study of Cisplatin and Carboplatin in Cervical Cancer, sponsored by University Health Network, Toronto. Recruiting at 4 sites in 2 countries. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-08-12.
Sponsored by University Health Network, Toronto · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies testing cisplatin in Uterine Cervical Neoplasms — 10 open to participants now, 11 under way, 3 of them phase 3. Cisplatin · Uterine Cervical Neoplasms.
Among the 80 studies testing cisplatin in Uterine Cervical Neoplasms, this one is the 47th largest by planned enrollment of the 73 interventional ones that give a count, is one of 2 that started in 2020, is one of 7 with no phase, reaches primary completion later than 5 of the 10 other live ones, and was the 71st registered.
2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.
Browse Uterine Cervical Neoplasms studies →10 of the 80 studies testing cisplatin in Uterine Cervical Neoplasms are open now, in 6 countries. Recruiting first, the newest first:
Denise Fabian · Sites in United States
Ages 18–120 · Women only
Hospital do Coracao · Sites in Brazil
Ages 18–70 · Women only
Tata Memorial Centre · Sites in India
Ages 18–80 · Women only
Chuangzhen Chen · Sites in China
Ages 18–70 · Women only
Chongqing University Cancer Hospital · Sites in China
Ages 18–75 · Women only
By country, each count listing its studies:
Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →
Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.
This study: 18 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 34 · Phase 3 21 · Phase 4 1
First in 1996; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 31 is below the median of 100 across 1,740 interventional studies indexed under Uterine Cervical Neoplasms.
Median enrollment 50 across the 73 interventional studies. Of the 48 that completed or were terminated, 15 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 80 has an industry lead sponsor. The 10 most frequent:
University Health Network, Toronto is the lead sponsor of 1,441 studies on the registry; 298 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 3 (18%) have results posted.
18 studies in Uterine Cervical Neoplasms by University Health Network, Toronto: 2 open now, 6 under way, none of them phase 3. Of 12 finished, 0 (0%) have results posted.
Among the 18 studies in Uterine Cervical Neoplasms by University Health Network, Toronto, this one is the 9th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2020, is one of 8 with no phase, and was the 18th registered.
University Health Network, Toronto’s Uterine Cervical Neoplasms studies by the year they started, since 1995.
3 of the studies testing cisplatin in Uterine Cervical Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05764044Phase 3Hospital do CoracaoAdjuvant Chemotherapy in cfHPV-DNA Plasma Positive Patients: A Biomarker In Locally Advanced Cervical Cancer | 2026-12-31 |
| NCT04016389University Health Network, TorontoFIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery | 2026-12 |
| NCT04491942National Cancer Institute (NCI)Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 80 studies testing cisplatin in Uterine Cervical Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among University Health Network, Toronto’s 18 in Uterine Cervical Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will include patients with invasive cervical cancer that wish to keep their fertility as much as possible in the future after treatment.
Patients who receive surgery alone may experience long-term side effects including infertility. The purpose of this research study is to determine whether giving neo-adjuvant chemotherapy prior to surgery can maintain fertility in patients with invasive cervical cancer.
The neo-adjuvant chemotherapy will consist of a platinum-based chemotherapy drug cisplatin or carboplatin, with a chemotherapy drug called paclitaxel. These are common chemotherapy drugs used in the treatment of women with cervical cancers.
All participants will first receive neo-adjuvant platinum-based chemotherapy. Once the neo-adjuvant chemotherapy has been completed, participants will be assessed by imaging scans to see whether they have a response to the treatment.
If participants are responding to treatment, they will then have a trachelectomy. After surgery, participants will be assessed and the study doctor will determine whether adjuvant treatment is needed. Adjuvant treatment may include chemotherapy and radiotherapy, or have a hysterectomy done.
If participants do not respond to or their disease worsens after neo-adjuvant treatment, participants will receive adjuvant treatment with chemotherapy and radiotherapy or have a hysterectomy done.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Part 1 - Eligibility Criteria for Chemotherapy
Part 2 - Eligibility Criteria for Fertility Sparing Surgery (FSS)
Exclusion Criteria:
Part 1 - Exclusion Criteria for Chemotherapy
Part 2 - Exclusion Criteria for Fertility Sparing Surgery
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive neo-adjuvant treatment cisplatin or carboplatin with paclitaxel, intravenously, either once every cycle or once a week, for three (21-day) cycles. After neo-adjuvant treatment, depending on their status, participants may have the trachelectomy done. Adjuvant treatment may include standard chemotherapy and radiotherapy, or a hysterectomy may need to be done.
Drug: Cisplatin · Drug: Carboplatin · Drug: Paclitaxel · Procedure: Trachelectomy
Cisplatin is an antineoplastic agent that is commonly used for the treatment of cervical cancer.
Carboplatin is an antineoplastic agent that is commonly used for the treatment of cervical cancer.
Paclitaxel is an antineoplastic agent that is commonly used in combination with cisplatin or carboplatin for the treatment of cervical cancer.
Surgery to remove the cervix but keep the uterus intact.
Rate of functional uterus defined as successful fertility sparing surgery (FSS) with no adjuvant therapy
Time frame: 2 years
Number of side effects
By Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
Time frame: 2 years
Rate of completion of neo-adjuvant chemotherapy
Time frame: 2 years
Response rate following neo-adjuvant chemotherapy
By Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Time frame: 2 years
Rate of fertility sparing surgery
Time frame: 2 years
Surgical complication rate following fertility sparing surgery
By Clavien-Dindo classification of surgical morbidity
Time frame: 2 years
Rate of recurrence-free survival
Time frame: 2 years
Rate of recurrence-free survival
Time frame: 3 years
Overall survival for patients who undergo neo-adjuvant chemotherapy followed by fertility sparing surgery
Time frame: 2 years
Overall survival for patients who undergo neo-adjuvant chemotherapy followed by fertility sparing surgery
Time frame: 3 years
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2020 (actual). Primary completion is estimated for Dec 2026, 82 months after the start.
Of 446 non-industry interventional studies with no phase under Uterine Cervical Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's planned 82 months is above that.
Counting every sponsor, half of 462 studies reached it within 33 months; a quarter within 15 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cisplatin · Carboplatin · Paclitaxel
University Health Network, Toronto →